Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02535286
Title Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Age Groups:
Covered Countries USA

No variant requirements are available.